Protagonist Therapeutics, Inc PTGX
$155.10
+2.43%
at last close
Analyst Consensus
- Consensus Rating
- Buy (13 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $134.08
- Implied Upside
- -13.6%
- Price Target Range
- $82.00 – $186.00
- Analysts (12 mo)
- 13
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-10 | Truist SecuritiesSrikripa Devarakonda |
Maintains | Buy | $145 → $170 |
| 2026-08-10 | WedbushYun Zhong |
Maintains | Outperform | $118 → $173 |
| 2026-08-10 | Goldman Sachs Richard Law |
Upgrades | Neutral → Buy | $110 → $186 |
| 2026-08-06 | CitigroupGeoff Meacham |
Maintains | Buy | $130 → $175 |
| 2026-08-06 | BarclaysEtzer Darout |
Maintains | Overweight | $151 → $153 |
| 2026-07-14 | BarclaysEtzer Darout |
Maintains | Overweight | $119 → $151 |
| 2026-07-07 | Truist SecuritiesSrikripa Devarakonda |
Maintains | Buy | $121 → $145 |
| 2026-05-06 | CitizensJonathan Wolleben |
Maintains | Market outperform | $120 → $137 |
| 2026-05-06 | WedbushYun Zhong |
Maintains | Outperform | $112 → $118 |
| 2026-04-15 | Truist SecuritiesSrikripa Devarakonda |
Maintains | Buy | $110 → $121 |
| 2026-04-07 | Clear StreetKaveri Pohlman |
Maintains | Buy | $104 → $116 |
| 2026-03-19 | Leerink PartnersFaisal Khurshid |
Maintains | Outperform | $107 → $110 |
| 2026-03-19 | JP MorganBrian Cheng |
Maintains | Overweight | $95 → $106 |
| 2026-03-19 | CitigroupGeoff Meacham |
Maintains | Buy | $115 → $125 |
| 2026-03-19 | BarclaysEtzer Darout |
Maintains | Overweight | $113 → $119 |
| 2026-03-03 | Goldman Sachs Richard Law |
Maintains | Neutral | $65 → $95 |
| 2026-02-26 | TD CowenTara Bancroft |
Maintains | Buy | $90 → $100 |
| 2026-02-26 | BarclaysEtzer Darout |
Maintains | Overweight | $108 → $113 |
| 2026-02-26 | CitizensJonathan Wolleben |
Maintains | Market outperform | $102 → $112 |
| 2026-02-02 | JefferiesRoger Song |
Maintains | Buy | $95 → $118 |
| 2026-01-30 | HC Wainwright & Co.Douglas Tsao |
Maintains | Buy | $80 → $117 |
| 2026-01-05 | Truist SecuritiesSrikripa Devarakonda |
Maintains | Buy | $88 → $110 |
| 2025-12-17 | BarclaysEtzer Darout |
Maintains | Overweight | $88 → $108 |
| 2025-12-08 | CitigroupGeoff Meacham |
Maintains | Buy | $98 → $115 |
| 2025-11-10 | CitigroupGeoff Meacham |
Maintains | Buy | $96 → $98 |
| 2025-11-07 | JP MorganBrian Cheng |
Maintains | Overweight | $68 → $81 |
| 2025-11-07 | BarclaysEtzer Darout |
Maintains | Overweight | $72 → $88 |
| 2025-11-07 | CitizensJonathan Wolleben |
Maintains | Market outperform | $69 → $102 |
| 2025-10-28 | Truist SecuritiesSrikripa Devarakonda |
Maintains | Buy | $76 → $88 |
| 2025-10-28 | WedbushYun Zhong |
Maintains | Outperform | $70 → $86 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $155.10
- Market Cap
- $9.84 billion
- 52-Week Range
- $50.48 – $155.53
- Average Volume
- 627K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.